Rezurock
What Rezurock is used for
Rezurock is indicated for the treatment of adults and paediatric patients (12 years and older with a body weight of at least 40 kg) with chronic graft-versus-host disease (cGVHD) when other treatment options provide limited clinical benefit, are not suitable, or have been exhausted.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- Conditional approval: approved on less complete data because the need is high; more data must follow.
Key facts
- Brand
- Rezurock
- Active substance
- belumosudil
- Disease area
- Graft vs Host Disease
- Medicine group
- Immunosuppressants
- ATC code
- L04AA48
- Marketing authorisation holder
- Sanofi Winthrop Industrie
- Authorised in the EU since
- 2026
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Rezurock used for?
Rezurock is indicated for the treatment of adults and paediatric patients (12 years and older with a body weight of at least 40 kg) with chronic graft-versus-host disease (cGVHD) when other treatment options provide limited clinical benefit, are not suitable, or have been exhausted.
What is the active substance in Rezurock?
Rezurock contains belumosudil.
Who makes Rezurock?
The EU marketing authorisation holder is Sanofi Winthrop Industrie.
Is Rezurock an orphan medicine?
Yes. Rezurock is designated an orphan medicine in the EU, for a rare disease (Graft vs Host Disease).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU